Guselkumab for treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and drug-survival for up to 148 weeks [PDF]
, 2023 Background: Real-world data are useful to guide the management of psoriasis. Here, we present data on the effectiveness and survival of guselkumab in moderate-to-severe chronic plaque psoriasis for up to 148 weeks.
Belcastro A. +8 more
core +1 more source
A non-clinical comparative study of IL-23 antibodies in psoriasis
mAbs, 2021 Four antibodies that inhibit interleukin (IL)-23 are approved for the treatment of moderate-to-severe plaque psoriasis. Here, we present non-clinical data comparing ustekinumab, guselkumab, tildrakizumab and risankizumab with regard to thermostability ...
Li Zhou +19 more
doaj +1 more source
The role of IL-23 receptor signaling in inflammation-mediated erosive autoimmune arthritis and bone remodeling [PDF]
, 2017 The IL-23/Th17 axis has been implicated in the development of autoimmune diseases, such as rheumatoid arthritis (RA) and psoriatic arthritis (PsA). RA and PsA are heterogeneous diseases with substantial burden on patients.
Driel, M. (Marjolein) van +2 more
core +2 more sources
Consistent response to guselkumab treatment between Hispanic and non-Hispanic patients with psoriasis : an analysis from VOYAGE 1 and VOYAGE 2 [PDF]
, 2021 Altres ajuts: Janssen Research and Development (JRD)Introduction: In VOYAGE 1 (NCT02207231) and VOYAGE 2 (NCT02207244), guselkumab, an interleukin-23 blocker, was safe and effective in patients with moderate-to-severe plaque psoriasis.
Gooderham, M.J. +6 more
core +1 more source
Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis. [PDF]
, 2020 Risankizumab-rzaa (Skyrizi®; AbbVie) is a humanized IgG monoclonal antibody directed against interleukin-23p19 (IL-23p19) indicated for the treatment of moderate-to-severe psoriasis in adults who are candidates for systemic therapy or phototherapy.
Liao, Wilson +3 more
core +1 more source
Tumor necrosis factor inhibitors in psoriatic arthritis. [PDF]
, 2017 INTRODUCTION: Psoriatic arthritis (PsA) is a chronic inflammatory disease that can result in significant disability. With the emergence of tumor necrosis factor inhibitors (TNFi), therapeutic outcomes in PsA have improved substantially.
Kraft, Walter K. +2 more
core +2 more sources
RNA aptamer delivery through intact human skin [PDF]
, 2018 It is generally recognised that only relatively small molecular weight (typically 100,000-fold) and aptamer integrity was confirmed using an oligonucleotide precipitation assay.
Brown, M. B. +12 more
core +3 more sources
, 2016 Rheumatoid arthritis is a chronic inflammatory joint disease, which can cause cartilage and bone damage as well as disability. Early diagnosis is key to optimal therapeutic success, particularly in patients with well-characterised risk factors for poor ...
Aletaha, Daniel +2 more
core +1 more source
Translational opportunities for targeting the Th17 axis in acute graft-vs.-host disease [PDF]
, 2016 International audienceAllogeneic stem cell transplantation (allo-SCT) is a curative therapy for different life-threatening malignant and non-malignant hematologic disorders.
Gaugler, Béatrice +3 more
core +4 more sources
Interleukin 23-Helper T Cell 17 Axis as a Treatment Target for Pityriasis Rubra Pilaris. [PDF]
, 2017 Treatment of pityriasis rubra pilaris (PRP) is solely based on its resemblance to psoriasis rather than any knowledge of its pathomechanism. Insight into pathogenic mediators of inflammation is essential for targeted and valid treatment options that ...
Conrad, C. +8 more
core +2 more sources